Michael Kauffman

Michael G.
Kauffman was the founder of Karyopharm Therapeutics, Inc., founded in 2008, where the title held was Director from 2021 to 2022.
Dr. Kauffman is also the founder of Millennium Predictive Medicine, Inc...
Current positions include President, Chief Executive Officer & Director at Nereid Therapeutics, Inc. since 2023; Non-Executive Chairman at BiVictriX Therapeutics Plc since 2023; Director at Kyntra Bio, Inc. starting 2025; Director at FoRx Therapeutics AG; Director at Incendia Therapeutics, Inc.; Director & President-Development at Verastem, Inc. since 2012; and Director at Mirror Biologics Inc. Former roles include President & Chief Executive Officer at Predix Pharmaceuticals, Inc.; President & Chief Executive Officer at EPIX Pharmaceuticals, Inc. from 2002 to 2008; Medical Director at Biogen, Inc. from 1995 to 1997; Director at CombinatoRx, Inc. from 2006 to 2009; Director at Metamark Genetics, Inc. in 2012; Independent Director at Infinity Pharmaceuticals, Inc. from 2017 to 2020; Director at Zalicus, Inc. from 2006 to 2014; Director at Excision BioTherapeutics, Inc.; Independent Director at Adicet Bio, Inc. from 2021 to 2024; Independent Director at Kezar Life Sciences, Inc. from 2016 to 2026; Advisor at Bessemer Venture Partners LP from 2009 to 2010; Executive Vice President-Distribution Operations at The Jones Group, Inc.; Vice President-Clinical at Millennium Pharmaceuticals, Inc. from 2000 to 2002; Chief Medical Officer at Onyx Pharmaceuticals, Inc. from 2009 to 2010; Advisor at Prime Movers Lab LLC; and Chief Medical Officer at Proteolix, Inc. from 2008 to 2009.
Education includes undergraduate studies at Amherst College and a doctorate from The Johns Hopkins University School of Medicine conferred in 1992.